The goal of topical corticosteroid therapy is to maximise the clinical benefits of this highly effective group of drugs, while minimising their adverse effects. Many types of steroid-induced skin lesions and skin atrophy can occur by such mechanisms as the suppression of cell proliferation, immunosuppression, or hormonal activity, and a trend towards an increased incidence of steroid-induced dermatological disturbances has been observed in recent years. Systemic effects have also been documented.
To reduce the risk of local and systemic effects, it is necessary to consider factors such as the intrinsic potency of a drug, type of vehicle used and frequency of application. A potent drug may be changed to a less potent one, or the dosage reduced. Once-daily application is often as effective as three-times-daily application, and intermittent application can also be recommended.
The concept of an ‘ante-drug’ promises new developments in topical corticosteroid therapy. An ‘ante-drug’, e.g. difluprednate, has potent efficacy but fewer side effects than conventional therapy, since it acts at the application site and then is metabolised to less active or inactive compounds before reaching the systemic circulation. It is likely that future corticosteroids will have the attributes of an ante-drug, thus greatly reducing the risk of systemic effects. At present, however, it is still necessary to recognise the influence of various drug and patient factors that contribute to side effects, in order to balance clinical efficacy with an acceptable side effect profile.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Fredriksson T, Lassus A, Bleeker J. Treatment of psoriasis and atopic dermatitis with halcinonide cream applied once and three times daily. British Journal of Dermatology 102: 575–578, 1980
Frosch PJ, Wendt H, Kligman AM. The Duhring chamber test for assaying corticosteroid atrophy in humans, p. 185, Academic Press Inc., London, 1981
Fujino A, Ohta S, Shinozawa N, Mukouyama H, Yanagida Y, el al. Studies on the metabolic fate of difluprednate (DFBA) (2): absorption, distribution and excretion after dermal application to rats and rabbits. Oyo Yakuri 29: 701–712, 1985
Fujino A, Ohta S, Shibata K, Ichihara N, Gotoh A, et al. Studies on the metabolic fate of difluprednate (DFBA) (3): metabolism in rats and rabbits after subcutaneous administration. Oyo Yakuri 29: 713–723, 1985
Harada S, Kukita J, Shimao S, Takeda K, Miura H, et al. The result of a double blind clinical comparative study with topical 0.1% hydrocortisone 17-butyrate 21-propionate (Pandel ointment and cream). Nishinihon Journal of Dermatology 44: 644–656, 1982
Kirby JD, Munro DD. Steroid-induced atrophy in an animal and human model. British Journal of Dermatology 94(Suppl. 12): 111–119, 1976
Kohda H, Fukuda H, Hino Y, Urabe H. Adverse effects of topical corticosteroids. Nishinihon Journal of Dermatology 40: 177–187, 1978
Lee HJ, Soliman MR. Anti-inflammatory steroids without pituitary-adrenal suppression. Science 215: 989–991, 1982
McKenzie AW, Atkinson RM. Topical activities of betamethasone esters in man. Archives of Dermatology 89: 741–746, 1964
McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Archives of Dermatology 86: 608–610, 1962
Takeda K. Cautions upon continued and prolonged use of the drug — topical corticosteroids. Clinical Drug Intelligence 2: 92–98, 1983
Takeda K. Various topical steroids and their evaluation of clinical effects. Rinsho Derma (Tokyo) 26: 631–647, 1984
Takeda K. Methaderm® symposium, Tokyo, 3rd April, 1987. Excerpta Medica Conference Bulletins, Excerpta Medica, 1987
Takeda K, Aii S. Chemical structure and biological activity of topical corticoids. Nishinihon Journal of Dermatology 40: 793–805, 1978
Takeda K, Harada T, Asato T, Ishimoto A, Nomoto M. Review on systemic effects of topical corticosteroids — with special reference to adrenocortical suppression following percutaneous absorption. Journal of Clinical and Experimental Medicine 101: 817–829, 1977
Takeda K, Arase S, Nagai R. Usefulness of topical steroids and their application — with special reference to new topical steroids. Progress Medical 6: 3007–3014, 1986
Takeda K, Arase S, Nagai R. How to use topical steroids. Japan Medical Journal 3313: 3–10, 1987a
Takeda K, Kukita A, Asada Y, Shimao S, Watanabe Y, et al. Studies on clinical efficacy and percutaneous systemic and/or topical effects of a new synthetic corticoid. Abstract, part II. 17th World Congress of Dermatology, p. 325, 1987b
Van der Harst LCA, de Jonge H, Pot F, Polano MK. Comparison of two application schedules for clobetasol 17 propionate. Acta Dermato-Venereologica 62: 270–273, 1982
von Hinz E, Lubach D. Untersuchungen über Entstehung und Rückbildung der dermalen Kortikosteroid-Atrophie. Dermatosen 34: 174–178, 1986
Watanabe Y, Ohkawara A, Toda K, Sakuma M, Mizuno J, et al. A double blind clinical comparative study with hydrocortisone 17-butyrate 21-propionate (HBP). Skin Research 23: 828–844, 1981
Woodford R, Haigh JM, Barry BW. Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications. Dermatologica 166: 136–140, 1983
About this article
Cite this article
Takeda, K., Arase, S. & Takahashi, S. Side Effects of Topical Corticosteroids and their Prevention. Drugs 36, 15–23 (1988). https://doi.org/10.2165/00003495-198800365-00005
- Topical Corticosteroid
- Beclomethasone Dipropionate
- Skin Atrophy
- Clobetasol Propionate
- Betamethasone Valerate